Detailed company information
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 29, 2026
Earnings Transcript for 2025 - Q4Released: Feb 24, 2026
Earnings Transcript for 2025 - Q3Released: Oct 29, 2025
Earnings Transcript for 2025 - Q2Released: Aug 05, 2025
Earnings Transcript for 2025 - Q1Released: May 09, 2025
Earnings Transcript for 2024 - Q4Released: Feb 25, 2025
Earnings Transcript for 2024 - Q3Released: Nov 09, 2024
Earnings Transcript for 2024 - Q2Released: Aug 08, 2024
Earnings Transcript for 2024 - Q1Released: May 02, 2024
Earnings Transcript for 2023 - Q4Released: Mar 05, 2024
Earnings Transcript for 2023 - Q3Released: Nov 07, 2023
Earnings Transcript for 2023 - Q2Released: Aug 07, 2023
Earnings Transcript for 2023 - Q1Released: May 09, 2023
Earnings Transcript for 2022 - Q4Released: Mar 14, 2023
Earnings Transcript for 2022 - Q3Released: Nov 08, 2022
Earnings Transcript for 2022 - Q2Released: Aug 06, 2022
Earnings Transcript for 2022 - Q1Released: May 07, 2022
Earnings Transcript for 2021 - Q4Released: Feb 22, 2022
Earnings Transcript for 2021 - Q3Released: Nov 03, 2021
Earnings Transcript for 2021 - Q2Released: Aug 05, 2021
Earnings Transcript for 2021 - Q1Released: May 09, 2021
Earnings Transcript for 2020 - Q4Released: Feb 22, 2021
Earnings Transcript for 2020 - Q3Released: Nov 01, 2020
Earnings Transcript for 2020 - Q2Released: Aug 05, 2020
LUNG Pulmonx Corporation
RXST RxSight, Inc.
SIBN SI-BONE, Inc.
KIDS OrthoPediatrics Corp.
AORT Artivion, Inc.
OFIX Orthofix Medical Inc.
ANIK Anika Therapeutics, Inc.
TMCI Treace Medical Concepts, Inc.
ITGR Integer Holdings Corporation
CNMD CONMED Corporation
LIVN LivaNova PLC
ATEC Alphatec Holdings, Inc.